Amundi Asset Management US’s Sarepta Therapeutics SRPT Stock Holding History

Amundi Asset Management US’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$3.94M	Buy	52,928 +12,027	+29%	+$1.11M	﹤0.01%	1072
2020 Q4	$6.97M	Buy	40,901 +9,401	+30%	+$1.39M	0.01%	887
2020 Q3	$4.42M	Sell	31,500 -163,495	-84%	-$24.8M	﹤0.01%	929
2020 Q2	$31.3M	Buy	194,995 +18,131	+10%	+$2.47M	0.04%	414
2020 Q1	$17.3M	Buy	176,864 +3,935	+2%	+$450K	0.03%	431
2019 Q4	$22.3M	Buy	172,929 +1,816	+1%	+$183K	0.03%	525
2019 Q3	$12.9M	Sell	171,113 -23,732	-12%	-$2.8M	0.02%	639
2019 Q2	$29.6M	Buy	194,845 +40,234	+26%	+$4.89M	0.02%	469
2019 Q1	$18.4M	Buy	154,611 +38,194	+33%	+$4.91M	0.03%	541
2018 Q4	$12.7K	Sell	116,417 -295	-0.3%	-$36.9K	0.01%	584
2018 Q3	$18.9M	Buy	116,712 +13,294	+13%	+$1.82M	0.02%	553
2018 Q2	$13.7M	Buy	103,418 +53,756	+108%	+$5.07M	0.02%	633
2018 Q1	$3.68M	Buy	+49,662	New	+$3.31M	0.01%	929

Other funds holding SRPT

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Amundi Asset Management US's SRPT Position: Q1 2021 in Review

Amundi Asset Management US increased its Sarepta Therapeutics (SRPT) stake by 29% in Q1 2021, buying an estimated $1.11M and bringing the position to 52,928 shares worth $3.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1072.

Amundi Asset Management US first reported a position in SRPT in Q1 2018 and has held it in 13 quarters since. The position peaked at $31.3M in Q2 2020. 367 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

Amundi Asset Management US held 52,928 shares of Sarepta Therapeutics worth $3.94M as of Q1 2021.
Amundi Asset Management US bought 12,027 Sarepta Therapeutics shares in Q1 2021, an estimated $1.11M.
Sarepta Therapeutics made up ﹤0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #1072 holding.
Amundi Asset Management US first reported a position in Sarepta Therapeutics in Q1 2018 and has held it in 13 quarters since.
Amundi Asset Management US's Sarepta Therapeutics position peaked at $31.3M in Q2 2020.
367 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.